Patients with advanced NSCLC harboring HER2 mutations exhibit poor responses to conventional chemotherapy and immunotherapy, hence targeted therapies against HER2 are under extensive investigation. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.